Smiths Group share price: Revenue and profits fall in line with expectations
Smiths Group (LON:SMIN) has this morning updated investors on its half-year performance, posting a drop in revenue and headline operating profit.
**Highlights from the company statement:**
· Revenue and headline operating profit down in line with expectations; John Crane impacted by challenging oil and gas markets, although aftermarket revenues proved more resilient; operating margin down 330bps to 19.9%; Continued growth at Smiths Medical; operating margin up 150bps to 20.5%;
Good profit growth at Smiths Detection; operating margin up 210bps to 12.4%; Cash conversion strong at 101%; headline free cash flow up 32% to £174m; Pension trustee negotiations concluded; £50m cash flow improvement from FY17; Interim dividend increased 2% to 13.25 pence per share.
Smiths Group Chief Executive Andy Reynolds Smith said:
“In my first six months at Smiths Group, I have visited many of our sites around the world, meeting over a thousand colleagues and listening to our customers. I have been highly impressed by our cutting edge technologies, our market leading positions, the depth of experience and expertise of our people and the strength of our customer relationships. I am confident that we can unlock substantial value through improving our operational efficiency, which will generate resources to invest in growth. Overall, the Group will drive simplification and speed to promote adaptability and innovation.
“From a trading perspective, this is a solid set of results. Group performance in the first six months of the year demonstrated the benefits of our range of end market exposures. As expected, John Crane was down in the first half, in persistently tough oil and gas end markets, but we benefited from growth in profits at Smiths Medical and Smiths Detection. Good progress has been made to improve Smiths Detection’s competitive positioning through initiatives on value engineering, programme management and aftermarket servicing, which are clearly having a positive impact on the bottom line. Against a tough prior year comparator, Smiths Medical delivered another strong performance as it benefited from consumables sales for its expanded installed base of infusion pumps. Performance at Smiths Interconnect and Flex-Tek was in line with expectations.
“As previously stated, Group performance is anticipated to be slightly more weighted to the second half than usual. We expect global energy markets to remain challenging in the second half of the year, and are taking action to ensure that John Crane remains well positioned in an uncertain environment. I expect Smiths Medical to deliver a similar revenue performance in the second half, driven by growth in Infusion Systems and Vital Care. Smiths Medical’s margins should benefit further from the effect of operational efficiencies and restructuring actions. Smiths Detection’s strong order book underpins anticipated higher levels of sales growth in the second half, although the margins seen in the first half will moderate somewhat given contract mix and investment in new business capabilities. Our expectations for the full year remain unchanged.”
As of 07:25 GMT, Wednesday, 16 March, Smiths Group plc share price is 1,077.00p.